HEMABATE (carboprost tromethamine) by Pfizer is clinical pharmacology carboprost tromethamine administered intramuscularly stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. Approved for postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. First approved in 1979.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
HEMABATE (carboprost tromethamine) is a prostaglandin analog administered intramuscularly that stimulates uterine myometrial contractions to manage postpartum hemorrhage refractory to conventional treatments. It works by directly contracting uterine smooth muscle to achieve hemostasis at the placentation site. The drug is indicated specifically for postpartum hemorrhage due to uterine atony when standard interventions have failed.
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating contraction phase for commercial teams.
CLINICAL PHARMACOLOGY Carboprost tromethamine administered intramuscularly stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. Whether or not these contractions result from a direct effect of carboprost on the myometrium has not…
Worked on HEMABATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
HEMABATE presents limited career opportunity with zero identified linked job openings and approaching loss of exclusivity. Roles on this product are primarily defensive, focused on protecting market share and managing the transition to generic competition rather than driving growth.